- Home
- CFR vs LEGN Comparison
CFR vs LEGN Comparison
Compare CFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | LEGN |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | 6008 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CFR | LEGN |
|---|---|---|
| Price | $140.03 | $18.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $142.31 | $63.08 |
| AVG Volume (30 Days) | 433.7K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.72 | $43.65 |
| Revenue Next Year | $4.70 | $32.75 |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $101.76 | $16.24 |
| 52 Week High | $148.97 | $45.30 |
Technical Indicators
Market Signals| Indicator | CFR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 52.65 |
| Support Level | $124.16 | $17.46 |
| Resistance Level | $140.27 | $20.39 |
| Average True Range (ATR) | 2.67 | 0.72 |
| MACD | 0.99 | 0.17 |
| Stochastic Oscillator | 98.70 | 73.68 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of December 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.